MVA
TEVA icon

Mount Vernon Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Mount Vernon Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,008
Closed -$69K – 50
2019
Q3 		$69K Sell
10,008
-300
-3% -$2.3K 0.1% 49
2019
Q2 		$95K Sell
10,308
-500
-5% -$6.03K 0.14% 51
2019
Q1 		$169K Buy
10,808
+500
+5% +$8.82K 0.26% 50
2018
Q4 		$159K Hold
10,308
– – 0.28% 49
2018
Q3 		$222K Sell
10,308
-1,000
-9% -$23.2K 0.33% 48
2018
Q2 		$275K Buy
11,308
+851
+8% +$17.4K 0.43% 42
2018
Q1 		$179K Sell
10,457
-250
-2% -$4.88K 0.28% 49
2017
Q4 		$203K Sell
10,707
-1,166
-10% -$17.5K 0.31% 50
2017
Q3 		$209K Sell
11,873
-587
-5% -$13.2K 0.35% 51
2017
Q2 		$414K Buy
12,460
+2,144
+21% +$66.4K 0.74% 36
2017
Q1 		$331K Sell
10,316
-608
-6% -$20.7K 0.61% 40
2016
Q4 		$396K Sell
10,924
-200
-2% -$7.99K 0.78% 38
2016
Q3 		$512K Sell
11,124
-1,438
-11% -$75K 1.06% 36
2016
Q2 		$631K Buy
12,562
+619
+5% +$33K 1.35% 34
2016
Q1 		$639K Sell
11,943
-400
-3% -$23.5K 1.42% 34
2015
Q4 		$810K Hold
12,343
– – 1.77% 28
2015
Q3 		$697K Buy
12,343
+512
+4% +$33.2K 1.62% 28
2015
Q2 		$699K Hold
11,831
– – 1.51% 33
2015
Q1 		$737K Buy
11,831
+550
+5% +$32K 1.59% 33
2014
Q4 		$649K Buy
11,281
+350
+3% +$19.5K 1.49% 31
2014
Q3 		$588K Buy
10,931
+100
+0.9% +$5.3K 1.46% 33
2014
Q2 		$568K Sell
10,831
-50
-0.5% -$2.56K 1.45% 33
2014
Q1 		$575K Sell
10,881
-225
-2% -$10.4K 1.5% 33
2013
Q4 		$445K Sell
11,106
-650
-6% -$25.6K 1.16% 38
2013
Q3 		$444K Sell
11,756
-33,090
-74% -$1.29M 1.35% 34
2013
Q2 		$1.76M Buy
+44,846
New +$1.75M 1.9% 28

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Mount Vernon Associates's TEVA Position: Q4 2019 in Review

Mount Vernon Associates sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 10,008 shares — an estimated $69K sold.

Mount Vernon Associates first reported a position in TEVA in Q2 2013 and held it in 26 quarters. The position peaked at $1.76M in Q2 2013. 437 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

  • Mount Vernon Associates reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Mount Vernon Associates sold 10,008 Teva Pharmaceuticals shares in Q4 2019, an estimated $69K.
  • Mount Vernon Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 26 quarters.
  • Mount Vernon Associates's Teva Pharmaceuticals position peaked at $1.76M in Q2 2013.
  • 437 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Mount Vernon Associates's 13F filing for Q4 2019, filed 24 Jan 2020.